PD-1およびPDL1阻害剤／免疫チェックポイント阻害剤の世界市場レポート 2025年

PD-1およびPDL1阻害剤／免疫チェックポイント阻害剤の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR14.7％で919億7,000万米ドルに成長します。予測期間の成長は、適応症の拡大、バイオマーカー調査と個別化医療、臨床試験と研究協力、世界のヘルスケアインフラ開発に起因しています。予測期間中の世界の動向としては、患者へのアクセスと購入しやすい価格、世界の臨床試験協力、免疫療法の併用、患者中心のアプローチ、規制の更新、承認への注目などが挙げられます。

PD-1およびPD-L1阻害剤（免疫チェックポイント阻害剤とも呼ばれる）市場の成長予測は、がん患者の急増に大きく影響されています。制御不能な細胞増殖と播種を特徴とするがんは、近年顕著に増加しています。PD-1阻害剤とPD-L1阻害剤は、がん細胞と効果的に闘うために身体の免疫システムを活用することで、がん治療に重要な役割を果たしています。例えば、EUサイエンス・ハブが2023年10月に発表した調査結果によると、過去2年間に新たに発生したがん患者は2.3％増の274万人に達し、がん関連死は2.4％増加しました。このがん罹患率の急増は、PD-1およびPD-L1阻害剤市場の成長予測に大きく寄与しています。

PD-1およびPD-L1阻害剤市場の成長予測は、個別化医療の重視の高まりと密接に結びついています。この先進ヘルスケア・アプローチは、治療戦略において遺伝、行動、環境の影響といった患者固有の要因を考慮するものです。PD-1阻害剤とPD-L1阻害剤の文脈では、個別化医療は、個々の患者の特性やバイオマーカーの発現に基づいて、有効性を最適化し、潜在的な副作用を最小化するようにがん治療を調整することを含みます。2023年2月の個別化医療連合（Personalized Medicine Coalition）のデータでは、2022年に米国FDAが新たに承認した医薬品の34％を個別化医療が占めており、持続的な増加傾向を示しています。このような個別化医療への注目の高まりは、PD-1およびPD-L1阻害剤市場を大きく前進させる。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界PD-1およびPDL1阻害剤／免疫チェックポイント阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のPD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場：成長率分析
• 世界のPD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場の実績：規模と成長, 2019-2024
• 世界のPD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界PD-1およびPDL1阻害剤／免疫チェックポイント阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のPD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ニボルマブ
• ペムブロリズマブ
• アテゾリズマブ
• アベルマブ
• デュルバルマブ
• 世界のPD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のPD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肺がん
• 膀胱がん
• 悪性黒色腫
• ホジキンリンパ腫
• 大腸がん
• その他の用途
• 世界のPD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 学術調査機関
• 世界のPD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場ニボルマブの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単独療法
• 併用療法
• 世界のPD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場、ペムブロリズマブの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単独療法
• 併用療法
• 世界のPD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場アテゾリズマブの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単独療法
• 併用療法
• 世界のPD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場、アベルマブのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単独療法
• 併用療法
• 世界のPD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場、デュルバルマブの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単独療法
• 併用療法

第7章 地域別・国別分析

• 世界のPD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のPD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• PD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場：競合情勢
• PD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場：企業プロファイル
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Merck and Company Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Gilead Sciences Inc.
• AstraZeneca plc
• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline Plc
• Regeneron Pharmaceuticals Inc.
• BeiGene Ltd
• Shanghai Jhunsi Biosciences Ltd.
• Akeso Inc.
• Alphamab Oncology
• Eli Lilly and Company
• Boehringer Ingelheim
• Xencor Inc.
• Taiga Biotechnologies Inc.
• Jiangsu Alphamab Biopharmaceuticals Co. Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• PD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場2029：新たな機会を提供する国
• PD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場2029：新たな機会を提供するセグメント
• PD-1およびPDL1阻害剤／免疫チェックポイント阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

PD-1 and PDL1 inhibitors, also known as immune checkpoint inhibitors, belong to the class of immunotherapy drugs employed in cancer treatment. They function by directing the immune system to identify and combat cancer cells effectively. Widely applied across various cancer conditions, these therapies serve as vital components in cancer treatment protocols.

Key products within the PD-1 and PDL1 inhibitor category include nivolumab, pembrolizumab, atezolizumab, avelumab, and durvalumab. Nivolumab, specifically a PD-1 inhibitor, operates by impeding the PD-1 receptor present on T cells, thereby thwarting cancer cells' ability to evade immune system attacks. These inhibitors find application in treating a spectrum of cancers such as lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, colorectal cancer, among others.

These immunotherapy drugs are available through various channels including hospital pharmacies, retail pharmacies, and online platforms. They are predominantly utilized within hospital settings, specialty clinics, as well as academic and research institutions, constituting integral elements in comprehensive cancer care and research endeavors.

The PD-1 and PDL1 inhibitors/ immune checkpoint inhibitors market size has grown rapidly in recent years. It will grow from$45.8 billion in 2024 to $53.15 billion in 2025 at a compound annual growth rate (CAGR) of 16.0%. The growth in the historic period can be attributed to immunotherapy advancements, increased clinical success and approvals, increased cancer incidence, a shift in cancer treatment paradigm, collaborations, and research investments

The PD-1 and PDL1 inhibitors/ immune checkpoint inhibitors market size is expected to see rapid growth in the next few years. It will grow to $91.97 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to expanding indications, biomarker research and personalized medicine, clinical trials and research collaborations, and global healthcare infrastructure development. Major trends in the forecast period include a focus on patient access and affordability, global clinical trial collaborations, immunotherapy combinations, patient-centric approaches, regulatory updates, and approvals.

The projected growth in the PD-1 and PD-L1 Inhibitors, also known as Immune Checkpoint Inhibitors, market is heavily influenced by the escalating prevalence of cancer cases. Cancer, characterized by uncontrolled cell growth and dissemination, has seen a noticeable increase in cases over recent years. PD-1 and PD-L1 inhibitors play a crucial role in treating cancer by leveraging the body's immune system to combat cancer cells effectively. For example, as per the European Union Science Hub's findings in October 2023, the preceding two years witnessed a 2.3% rise in new cancer cases, reaching 2.74 million, alongside a 2.4% increase in cancer-related deaths. This surge in cancer incidence significantly contributes to the growth anticipated in the PD-1 and PD-L1 Inhibitors market.

The anticipated growth in the PD-1 and PD-L1 Inhibitors market is closely tied to the increasing emphasis on personalized medicine. This advanced healthcare approach considers unique patient factors such as genetics, behaviors, and environmental influences in treatment strategies. In the context of PD-1 and PD-L1 inhibitors, personalized medicine involves tailoring cancer therapies to optimize efficacy and minimize potential adverse effects based on individual patient characteristics and biomarker expressions. Notably, the Personalized Medicine Coalition's data from February 2023 revealed that personalized medications accounted for 34% of newly approved pharmaceuticals by the US FDA in 2022, showcasing a sustained upward trend. This growing focus on personalized medicine significantly drives the PD-1 and PD-L1 Inhibitors market forward.

Product innovation has emerged as a pivotal trend shaping the landscape of PD-1 and PD-L1 Inhibitors, or immune checkpoint inhibitors. Leading market players are strategically channeling efforts towards developing innovative products to bolster their market presence. For instance, Bristol-Myers Squibb's successful FDA approval for Opdualag in March 2022 marked a breakthrough-a fixed-dose combination of nivolumab (Opdivo) and relatlimab, the latter being a LAG-3 inhibitor. Opdualag, the first LAG-3 inhibitor approved by the US FDA for treating metastatic melanoma, aims to augment immune responses against cancer cells, showcasing a substantial leap in product innovation within this sector.

Strategic investments play a crucial role in shaping the landscape of the PD-1 and PD-L1 Inhibitors market. Major companies operating in this domain are leveraging strategic initiatives to fortify their positions. For instance, Regeneron Pharmaceuticals, Inc.'s investment in June 2022 involved acquiring Sanofi's share in the Regeneron and Sanofi partnership concerning Libtayo (cemiplimab). This strategic move conferred Regeneron exclusive rights to develop, market, and manufacture Libtayo globally. Valued at $900 million, plus royalties and potential future milestone payments, this investment aimed to bolster Regeneron's foothold in the market. Libtayo, a first-in-class PD-1 inhibitor developed using Regeneron's VelocImmune technology, gained approval from the FDA and numerous global regulatory bodies, solidifying its position as a standard treatment for certain advanced non-small cell lung cancer, cutaneous squamous cell carcinoma, and basal cell carcinoma cases.

In June 2023, Coherus BioSciences, a leading U.S.-based biopharmaceutical company specializing in cancer therapeutics, acquired Surface Oncology for $65 million. This acquisition enhances Coherus' portfolio by incorporating innovative immuno-oncology therapies, including Surface's IL-27-targeted antibody (SRF388) and CCR8-targeted antibody (SRF114). With this acquisition, Coherus can now provide a diverse range of clinical-stage immunotherapies designed to boost the immune response against tumors, including applications for lung and liver cancer. Surface Oncology is a U.S.-based firm engaged in developing PD-1 and PD-L1 inhibitors, which are essential elements of immune checkpoint therapy for cancer treatment.

Major companies operating in the PD-1 and PDL1 inhibitors/ immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck and Company, F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., Gilead Sciences Inc., AstraZeneca plc, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc., BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd., Akeso Inc., Alphamab Oncology, Eli Lilly and Company, Boehringer Ingelheim, Xencor Inc., Taiga Biotechnologies Inc., Jiangsu Alphamab Biopharmaceuticals Co. Ltd, Dr. Reddy's Laboratories Ltd., Laekna Therapeutics, Genentech Inc., Tracon Pharmaceuticals Inc., Celgene, Hangzhou Sumgen Co. Ltd, Agenus Inc., BioNTech SE, Celldex Therapeutics Inc., CytomX Therapeutics Inc.

North America was the largest region in the PD-1 and PDL1 inhibitors market in 2024. The regions covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market consists of sales of various inhibitors such as cemiplimab, sintilimab, and camrelizumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Nivolumab; Pembrolizumab; Atezolizumab; Avelumab; Durvalumab
• 2) By Distribution Channel: Hospital pharmacies; Retail pharmacies; Online pharmacies
• 3) By Application: Lung Cancer; Bladder Cancer; Melanoma; Hodgkin Lymphoma; Colorectal Cancer; Other Applications
• 4) By End-Users : Hospitals; Specialty Clinics; Academic and Research Institutions
• Subsegments:
• 1) By Nivolumab: Monotherapy; Combination Therapy
• 2) By Pembrolizumab: Monotherapy; Combination Therapy
• 3) By Atezolizumab: Monotherapy; Combination Therapy
• 4) By Avelumab: Monotherapy; Combination Therapy
• 5) By Durvalumab: Monotherapy; Combination Therapy
• Companies Mentioned: Bristol-Myers Squibb Company; Merck and Company; F. Hoffmann-La Roche AG; Sanofi S.A.; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Characteristics

3. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Trends And Strategies

4. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Growth Rate Analysis
• 5.4. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Total Addressable Market (TAM)

6. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Segmentation

• 6.1. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nivolumab
• Pembrolizumab
• Atezolizumab
• Avelumab
• Durvalumab
• 6.2. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
• 6.3. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lung Cancer
• Bladder Cancer
• Melanoma
• Hodgkin Lymphoma
• Colorectal Cancer
• Other Applications
• 6.4. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Academic and Research Institutions
• 6.5. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Sub-Segmentation Of Nivolumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy
• 6.6. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Sub-Segmentation Of Pembrolizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy
• 6.7. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Sub-Segmentation Of Atezolizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy
• 6.8. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Sub-Segmentation Of Avelumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy
• 6.9. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Sub-Segmentation Of Durvalumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy

7. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Regional And Country Analysis

• 7.1. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 8.1. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 9.1. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 9.2. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 10.1. India PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 11.1. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 11.2. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 12.1. Australia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 13.1. Indonesia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 14.1. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 14.2. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 15.1. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 15.2. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 16.1. UK PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 17.1. Germany PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 18.1. France PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 19.1. Italy PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 20.1. Spain PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 21.1. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 21.2. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 22.1. Russia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 23.1. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 23.2. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 24.1. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 24.2. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 25.1. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 25.2. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 26.1. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 26.2. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 27.1. Brazil PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 28.1. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 28.2. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 29.1. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 29.2. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Landscape
• 30.2. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Company Profiles
  • 30.2.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Other Major And Innovative Companies

• 31.1. Gilead Sciences Inc.
• 31.2. AstraZeneca plc
• 31.3. Novartis AG
• 31.4. Pfizer Inc.
• 31.5. GlaxoSmithKline Plc
• 31.6. Regeneron Pharmaceuticals Inc.
• 31.7. BeiGene Ltd
• 31.8. Shanghai Jhunsi Biosciences Ltd.
• 31.9. Akeso Inc.
• 31.10. Alphamab Oncology
• 31.11. Eli Lilly and Company
• 31.12. Boehringer Ingelheim
• 31.13. Xencor Inc.
• 31.14. Taiga Biotechnologies Inc.
• 31.15. Jiangsu Alphamab Biopharmaceuticals Co. Ltd

32. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

34. Recent Developments In The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

35. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer